Search

everythinglearnresearchcommunity

for

Search:↓

Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.

Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.

R-spondins and their receptors help increase bone growth and may be used to treat bone loss diseases.

Topical minoxidil improves hair loss in 80% of women with breast cancer undergoing endocrine therapy.

Stopping the drug usually helps, but tamoxifen or surgery may be needed if symptoms persist.

Ritlecitinib is effective for long-term treatment of severe alopecia areata.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

Denosumab may cause alopecia areata.

Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.

Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.

Ritlecitinib helps hair regrowth and reduces emotional and functional burdens in alopecia areata.

Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Low-dose oral minoxidil can cause serious side effects like heart issues, so use the lowest effective dose.

Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.

Some dibenzo compounds might help treat cancer with fewer side effects.

Inhibitors of the enzyme 5 alpha-reductase could potentially treat disorders like prostate cancer and baldness.

CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.

Stopping finasteride improved seizure control, suggesting neurosteroids affect seizures and treatment.

5α-Reductase inhibitors, like finasteride, can cause serious, persistent side effects not always listed in official drug information.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.

ALRV5XR significantly improves hair density in women with hair loss and is well-tolerated.

5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.

The document's conclusion cannot be provided because the document is not available or cannot be read.

5-alpha-reductase inhibitors may help stabilize or slow down hair loss in some frontal fibrosing alopecia patients, but more research is needed to confirm their effectiveness and safety.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

The model improves understanding of androgen interactions by focusing on signal intensity and system capacity.

Eruca sativa oil, Aloe vera oil, and sodium carbonate may help improve cholesterol and tumor markers in breast cancer treatment.